Navigation Links
Novartis Class Awarded $250 Million in Punitive Damages
Date:5/19/2010

NEW YORK, May 19 /PRNewswire/ -- After delivering a unanimous verdict against Novartis on all counts and awarding 12 former Novartis sales reps $3.36 million in compensatory damages yesterday, a New York jury today delivered a stronger dose of the same medicine.  Announcing the amount of punitive damages to be awarded, the jury determined that Novartis must pay an additional $250 million for the gender discrimination it inflicted on 5,600 working women in the class. The case was the largest gender discrimination matter ever to go to verdict in the U.S.

Monday's sweeping verdict found Novartis liable for gender discrimination in pay, promotional opportunities and pregnancy-related matters. Today's punitive damage award is meant to punish the company for its past actions and to deter it and others from continuing to discriminate against female employees in the future.

The announcement of punitive damages came after Judge McMahon instructed jurors to consider the amount of punitive damages award in light of the offensiveness of Novartis' behavior, the nature and extent of the harm done, the length of time the class endured the behavior, the extent to which Novartis knew about the discrimination and how they reacted once they were on notice and the amount needed to deter repetition of Novartis' conduct in light of Novartis' financial condition.

The women were represented in the matter by David Sanford, Steven Wittels and Katherine Kimpel in the New York and Washington, D.C. offices of Sanford, Wittels & Heisler LLP, and

SOURCE Sanford Wittels & Heisler LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
5. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
6. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
7. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
10. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... 24, 2014 VolitionRx Limited (OTCQB: VNRX), ... cancer and other conditions, today announced that data from its ... for Business BioWin Day 2014, being held November 26, 2014 ... from VolitionRx,s lung cancer pilot study, the samples for which ... Universitaire (CHU) de Liege in Belgium . ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Switzerland, August 19 Arpida Ltd,(SIX: ARPN) announced today its financial results ... Key events 2009 to date, - Regulatory setback for ... under review, - Company restructuring completed, , ... June 2009 , CFO Harry Welten, MBA, commented: ...
... , WESTON, Fla., Aug. 19 In keeping with ... of families, America n Scientific Resources ... obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell ... and the Disintegrator Plus(TM). , , All ...
... , , LONDON, Aug. 19 ... the introduction of improved drugs to treat the disease. As healthcare ... companies conducting research on diabetes vaccines. If they succeed, the entire ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 3Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 2Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 3
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... have genetic evidence suggesting the antioxidant drugs currently ... the common cold can also help prevent and ... stressa culprit in driving tumor growth. ... loss of the tumor suppressor protein Caveolin-1 (Cav-1) ...
... the increasing incidence of antifungal-resistant infections, according to a ... . The essential oil shows a potent antifungal effect ... nail infections. Scientists from the University of Coimbra ... L,Hr shrub that grows in southern Portugal. The oil ...
... progressive trajectory is one of the most deeply-entrenched assumptions ... popular media by showing cavemen speaking in grunts and ... But is this assumption correct? Were the earliest ... a paper published in the latest issue of ...
Cached Biology News:Jefferson researchers provide genetic evidence that antioxidants can help treat cancer 2Jefferson researchers provide genetic evidence that antioxidants can help treat cancer 3Lavender oil has potent antifungal effect 2Earliest humans not so different from us, research suggests 2Earliest humans not so different from us, research suggests 3